ContraceptionPhase 4NCT02674139
Comparison Between Intrauterine Contraceptive Device Insertion During Cesarean Section Vs Conventional Application
A Phase 4 study testing Copper T 380A IUD in people with Contraception, run by sara AbdAllah.
Trial summary
The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Contraception
- What is being tested?
- Copper T 380A IUD
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- No sites listed yet
- Study dates
- Feb 2016to Jun 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 18 - 45 years.
- GA 36-40 weeks based upon the date of last normal menstruation, confirmed by ultrasonographic scan.
- Desire to have intrauterine contraceptive device (Cu T) after counseling about different contraceptive options and consented to the study.
Who cannot join
- Allergy to copper.
- Ante- or intra-partum hemorrhage.
- Hemorrhagic disorders.
- Current or past history of pelvic inflammatory disease.
- Women known to have pelvic TB.
- Known to have ruptured membranes for more than 24 h prior to delivery.
Show all 15Show fewer
- History of chorioamnionitis.
- Known uterine abnormalities e.g., Bicornuate/septate Uterus, uterine myoma.
- Patients presented with febrile morbidity prior to the operation defined as temperature above 38'c.
- Multiple pregnancies.
- Placenta previa.
- History of ectopic pregnancy.
- Anemia (hemoglobin <10 g/dl).
- Cervical cancer or carcinoma in situ.
- Diagnosis of active cervical infection for standard insertion.
About this study
Official title: Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application
The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and continuation rates) for women undergoing caesarean section.
Read the detailed description
- Study Design: A controlled randomized clinical trial (CRCT)
- Study Site: The study will be carried out in the Department of Obstetrics and Gynecology at Beni-suef University Hospital
- Study Population: The study population will include pregnant women between 36-40 weeks gestational ages who attend antenatal care and are eligible for insertion of IUCD during delivery through elective caesarean section.
- Study Sample: The study will consist of 200 women which will be chosen randomly to whom elective lower segment caesarean section will be done at the Obstetrics and Gynecology department, willing to have an intrauterine device (IUD) inserted for postpartum contraception and willing to comply with the study protocol.
After informed consent is obtained, eligible study participants will be randomized into 2 groups:
Group (A): 100 Women will receive the Pregna ® IUD at the 6 week postpartum visit Group (B): 100 Women will receive the Pregna ® IUD within 10 minutes of delivery of the placenta during caesarean section.
- Study Procedure:
Insertion Technique:
During caesarean section:
Uterine cavity will be inspected for presence of malformations following placental delivery, which would limit use of IUCD.The IUCD (Pregna Copper T 380A) will be removed from the insertion sleeve and will be placed on the sterile field. Uterus is stabilized by grasping it at fundus. Insertion will be done during cesarean delivery, after ex pulsion of placenta and through the uterine incision, manually (IUCD is Held between middle and index finger). It will be inserted into the uterus through uterine incision and will be released at fundus of uterus. Hand will be removed slowly from the uterus. Enough care will be taken not to dislodge IUCD as hand is removed. Strings will be guided toward the lower uterine segment without disturbing IUCD'S fundal position. Enough Care will be taken not to include IUCD strings during uterine closure.
Delayed postpartum IUDs Will be inserted in the usual sterile fashion as described in the manufacturer's instructions at the 6-week postpartum visit
Later Prior to Discharge:
- IUCD Client card, showing type of IUCD and date of insertion will be given to patient.
- She will be informed about the IUCD side effects and normal postpartum symptoms.
- Patients will be scheduled for a control examination at 1 week, 6 weeks, 3 months and 6 months after the insertion.
- She will be advised to contact one of the physicians immediately if they experienced:-
- Unusual vaginal discharge different from the usual lochia.
- Lower abdominal pain, especially if accompanied by fever or chills.
- Feeling of being pregnant.
- Suspicion that the IUCD has fallen out.
Follow up visits:
- At each visit the patients will be questioned for symptoms of expulsion, excessive bleeding and infection. In addition, a pelvic examination (per speculum) and trans-vaginal ultrasound will be performed at each follow-up visit.
- In per speculum examination if IUD threads are long, they will be cut 2 cm from external os. If threads of IUD are not seen and there was no history of expulsion of IUD, pelvic ultrasonography or X-ray pelvis will be done to note for misplaced IUD.
- All the patients will subjected to the follow up:
- The IUD will be removed in the case of partial expulsion, bleeding or pain, or at the patient's request.
- Ethical Considerations 1-Approval by the institution ethical committee 2-Individual Consent Process: Written informed consent will be taken after explaining the study objective the procedures to potential participants. Participation will be voluntary and participants will be informed that the decision not to participate will not impact on the quality of care they receive.
- The statistical Analysis:
Data will be statistically described in terms of mean + standard deviation (+/- SD), frequencies (number of cases) and relative frequencies (percentages) when appropriate. Comparison of numerical variables between the study groups will be done using Student t test for independent samples. For comparing categorical data, Chi square (X2) test will be performed. Exact test will be used instead when the expected frequency is less than 5. P values less than 0.05 will be considered statistically significant.
- Conditions
- Contraception
- Being tested
- Copper T 380A IUD
- Keywords
- post placental-caesarean-IUD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Copper T 380A IUDDevice
Also called Pregna
intrauterine contraceptive device T-shaped loaded with cupper
| Study group | Role | What they receive |
|---|---|---|
| IUD insertion 6 Weeks after delivery | Active comparator | Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later Receives: Device: Copper T 380A IUD |
| Immediate Post-placental insertion | Experimental | Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section. Receives: Device: Copper T 380A IUD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound
Complete IUD expulsion will be verified clinically and by transvaginal ultrasound. An IUD will be considered to be partially expelled if a distance greater than 10 mm is measured between the vertical arm of the IUD and the junction between the endometrium and the uterine cavity)
Measured: 6 months
Secondary outcomes (6)
Uterine perforation (assessed by pelvic ultrasonography or X-ray)
To be assessed by pelvic ultrasonography or X-ray pelvis will to note for misplaced IUD
Measured: 6 months
Pelvic pain (using the 0-10 Numeric Pain Rating Scale)
Using the 0-10 Numeric Pain Rating Scale and analgesic doses required
Measured: 6 months
Strings not visible (assessed by speculum examination)
To be assessed by speculum examination.
Measured: 6 months
Pelvic infection: number of participants with Pelvic infection
number of participants with Pelvic infection
Measured: 6 months
Psychological (satisfied or not) using questionnaire
using questionnaire
Measured: 6 months
Pregnancy (assessed by serum pregnancy test and pelvic ultrasound)
To be assessed by serum pregnancy test and pelvic ultrasound in suspicious cases (missed period - misplaced IUD - expelled IUCD either partial or complete)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2016 (estimated)
- Study startFeb 2016
- Primary completionMar 2017 (estimated)
- Study completionJun 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ContraceptionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 8 participants (estimated)
Sponsor and investigators
- Lead sponsor
- sara AbdAllah
- Sponsor type
- University, hospital or other
- Collaborators
- Beni-Suef University
- Responsible party
- Sponsor-investigator, sara AbdAllah, Beni-Suef University
- Investigators
- sara AA mohamed, master, Principal investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02674139
- Sponsor's protocol ID
- GO-MD-IUD
- Status last verified
- Sep 2016
- First submitted
- 30 Jan 2016
- Last updated
- 27 Sep 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application
- ClinicalTrials.gov ID
- NCT02674139
- Acronym / sponsor ID
- GO-MD-IUD
- Conditions
- Contraception
- Keywords
- post placental-caesarean-IUD
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 8 participants (estimated)
- Lead sponsor
- sara AbdAllahUniversity, hospital or other
- Collaborators
- Beni-Suef University
- Study start
- Feb 2016
- Primary completion
- Mar 2017 (estimated)
- Study completion
- Jun 2017 (estimated)
- First posted
- 4 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to compare immediate post-placental (within 10 minutes of placenta delivery) intrauterine contraceptive device (Copper T 380A) insertion versus conventional placement at 6 weeks (often referred to as delayed or interval insertion) regarding the clinical outcomes (safety, efficacy, expulsion and continuation rates) for women undergoing caesarean section.
Detailed description
- Study Design: A controlled randomized clinical trial (CRCT)
- Study Site: The study will be carried out in the Department of Obstetrics and Gynecology at Beni-suef University Hospital
- Study Population: The study population will include pregnant women between 36-40 weeks gestational ages who attend antenatal care and are eligible for insertion of IUCD during delivery through elective caesarean section.
- Study Sample: The study will consist of 200 women which will be chosen randomly to whom elective lower segment caesarean section will be done at the Obstetrics and Gynecology department, willing to have an intrauterine device (IUD) inserted for postpartum contraception and willing to comply with the study protocol.
After informed consent is obtained, eligible study participants will be randomized into 2 groups:
Group (A): 100 Women will receive the Pregna ® IUD at the 6 week postpartum visit Group (B): 100 Women will receive the Pregna ® IUD within 10 minutes of delivery of the placenta during caesarean section.
- Study Procedure:
Insertion Technique:
During caesarean section:
Uterine cavity will be inspected for presence of malformations following placental delivery, which would limit use of IUCD.The IUCD (Pregna Copper T 380A) will be removed from the insertion sleeve and will be placed on the sterile field. Uterus is stabilized by grasping it at fundus. Insertion will be done during cesarean delivery, after ex pulsion of placenta and through the uterine incision, manually (IUCD is Held between middle and index finger). It will be inserted into the uterus through uterine incision and will be released at fundus of uterus. Hand will be removed slowly from the uterus. Enough care will be taken not to dislodge IUCD as hand is removed. Strings will be guided toward the lower uterine segment without disturbing IUCD'S fundal position. Enough Care will be taken not to include IUCD strings during uterine closure.
Delayed postpartum IUDs Will be inserted in the usual sterile fashion as described in the manufacturer's instructions at the 6-week postpartum visit
Later Prior to Discharge:
- IUCD Client card, showing type of IUCD and date of insertion will be given to patient.
- She will be informed about the IUCD side effects and normal postpartum symptoms.
- Patients will be scheduled for a control examination at 1 week, 6 weeks, 3 months and 6 months after the insertion.
- She will be advised to contact one of the physicians immediately if they experienced:-
- Unusual vaginal discharge different from the usual lochia.
- Lower abdominal pain, especially if accompanied by fever or chills.
- Feeling of being pregnant.
- Suspicion that the IUCD has fallen out.
Follow up visits:
- At each visit the patients will be questioned for symptoms of expulsion, excessive bleeding and infection. In addition, a pelvic examination (per speculum) and trans-vaginal ultrasound will be performed at each follow-up visit.
- In per speculum examination if IUD threads are long, they will be cut 2 cm from external os. If threads of IUD are not seen and there was no history of expulsion of IUD, pelvic ultrasonography or X-ray pelvis will be done to note for misplaced IUD.
- All the patients will subjected to the follow up:
- The IUD will be removed in the case of partial expulsion, bleeding or pain, or at the patient's request.
- Ethical Considerations 1-Approval by the institution ethical committee 2-Individual Consent Process: Written informed consent will be taken after explaining the study objective the procedures to potential participants. Participation will be voluntary and participants will be informed that the decision not to participate will not impact on the quality of care they receive.
- The statistical Analysis:
Data will be statistically described in terms of mean + standard deviation (+/- SD), frequencies (number of cases) and relative frequencies (percentages) when appropriate. Comparison of numerical variables between the study groups will be done using Student t test for independent samples. For comparing categorical data, Chi square (X2) test will be performed. Exact test will be used instead when the expected frequency is less than 5. P values less than 0.05 will be considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| IUD insertion 6 Weeks after delivery | Active comparator | Device: Copper T 380A IUDSubjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later |
| Immediate Post-placental insertion | Experimental | Device: Copper T 380A IUDSubjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age: 18 - 45 years.
- GA 36-40 weeks based upon the date of last normal menstruation, confirmed by ultrasonographic scan.
- Desire to have intrauterine contraceptive device (Cu T) after counseling about different contraceptive options and consented to the study.
Key exclusion criteria (15 listed)
- Allergy to copper.
- Ante- or intra-partum hemorrhage.
- Hemorrhagic disorders.
- Current or past history of pelvic inflammatory disease.
- Women known to have pelvic TB.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Copper T 380A IUDAlso: Pregnaintrauterine contraceptive device T-shaped loaded with cupper | Device | IUD insertion 6 Weeks after delivery, Immediate Post-placental insertion |
Primary outcome
Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound
Time frame: 6 months
Complete IUD expulsion will be verified clinically and by transvaginal ultrasound. An IUD will be considered to be partially expelled if a distance greater than 10 mm is measured between the vertical arm of the IUD and the junction between the endometrium and the uterine cavity)
6 secondary outcomes
Uterine perforation (assessed by pelvic ultrasonography or X-ray)
Time frame: 6 months
Pelvic pain (using the 0-10 Numeric Pain Rating Scale)
Time frame: 6 months
Strings not visible (assessed by speculum examination)
Time frame: 6 months
Pelvic infection: number of participants with Pelvic infection
Time frame: 6 months
Psychological (satisfied or not) using questionnaire
Time frame: 6 months
Pregnancy (assessed by serum pregnancy test and pelvic ultrasound)
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Contraception
Not yet recruiting
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Contraceptive Behavior, Social Norms
Recruiting
Impact of Self-Care Family Planning Services on Health and Development in South Sudan (Family Planning Impact Lab)
Contraceptive Behavior, Self Administration
Not yet recruitingPhase 3
Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)
Contraception
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
Contraception
RecruitingObservational study
Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene Products
Primary Immune Deficiency Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
sara AA mohamed, master principal investigator
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Copper T 380A IUD in people with Contraception, run by sara AbdAllah.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Expulsion: Complete IUD expulsion will be verified clinically and by transvaginal ultrasound (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2016.